Evidence map›Paper›PMID 31038360›Full record

ReviewJournal of child and adolescent psychopharmacology2019

New Formulations of Stimulants: An Update for Clinicians.

Ronald Steingard, Sarper Taskiran, Daniel F Connor, John S Markowitz, Mark A Stein

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of child and adolescent psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Drug Interactions With Excessive Daytime Sleepiness Treatments.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Observational
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Effectiveness and safety of dexamphetamine sulfate (AttentinScandinavian journal of child and adolescent psychiatry and psychology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ronald Steingard1 Child Mind Institute, New York, New York.
Sarper Taskiran1 Child Mind Institute, New York, New York.
Daniel F Connor3 Division of Child and Adolescent Psychiatry, Department of Psychiatry University of Connecticut School of Medicine, Farmington, Connecticut.
John S Markowitz4 Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida.
Mark A Stein5 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington.

Funding

Intellectual and Developmental Disabilities Research CenterU54HD083091 · NICHD · UNIVERSITY OF WASHINGTON · PI DOHERTY, DANIEL · 2014 to 2019
$7.9M
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHDR01HD093612 · NICHD · UNIVERSITY OF FLORIDA · PI MARKOWITZ, JOHN S, ZHU, HAOJIE · 2018 to 2022
$3.0M
NICHD NIH HHS R01 HD093612NICHD NIH HHS U54 HD083091
6 · The paper itself

Abstract

In the last 15 years, there has been a marked increase in the number of available stimulant formulations with the emphasis on long-acting formulations, and the introduction of several novel delivery systems such as orally dissolving tablets, chewable tablets, extended-release liquid formulations, transdermal patches, and novel "beaded" technology. All of these formulations involve changes to the pharmaceutical delivery systems of the two existing compounds most commonly employed to treat attention-deficit/hyperactivity disorder (ADHD), amphetamine (AMP) and methylphenidate (MPH). In addition to these new formulations, our knowledge about the individual differences in response has advanced and contributes to a more nuanced approach to treatment. The clinician can now make increasingly informed choices about these formulations and more effectively individualize treatment in a way that had not been possible before. In the absence of reliable biomarkers that can predict individualized response to ADHD treatment, clinical knowledge about differences in MPH and AMP pharmacodynamics, pharmacokinetics, and metabolism can be utilized to personalize treatment and optimize response. Different properties of these new formulations (delivery modality, onset of action, duration of response, safety, and tolerability) will most likely weigh heavily into the clinician's choice of formulation. To manage the broad range of options that are now available, clinicians should familiarize themselves in each of these categories for both stimulant compounds. This review is meant to serve as an update and a guide to newer stimulant formulations and includes a brief review of ADHD and stimulant properties.

Indexed as

AmphetamineAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildDelayed-Action PreparationsDrug Administration ScheduleHumansMethylphenidateTabletsAmphetamineCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateTabletsattention-deficit/hyperactivity disorderpharmacokineticspharmacotherapyreviewstimulantstreatment

Identifiers

PMID31038360
PMCPMC7207053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.